Schizophrenia. Schizophrenia
Conditions
Interventions
Intervention 1: Both of group get antipsychotic Risperidone2-6 mg/day( Dr Abidi pharma) and placebo group received a similar placebo tablet daily. Intervention 2: Both of group get antipsychotic Rispe
Treatment - Drugs
Both of group get antipsychotic Risperidone2-6 mg/day( Dr Abidi pharma) and placebo group received a similar placebo tablet daily..
Both of group get antipsychotic Risperidone2-6 mg/day and intervention group were received bupropion 100-200mg/day( Dr Abidi pharma).
Sponsors
Vice chancellor for research of Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria were a DSM-IV-TR diagnosis of schizophrenia, smoking at least 10 cigarettes a day.exclusion criteria were major depressive, manic, or hypomanic episode, and seizure disorder. And having contraindications for use of bupropion.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Psychotic and anti-psychotic symptoms assessment. Timepoint: beginning of study, 14th and 28th day of study. Method of measurement: Brief psychiatric rating scale (BPRS).;Positive and Negative Symptoms Scale. Timepoint: beginning of study, 14th and 28th day of study. Method of measurement: Positive and Negative Symptoms Scale (PANSS).;Memory. Timepoint: in begging of study, 2nd, 7th, 14th, 28th of study. Method of measurement: ( WMS ) Wechsler Memory Scale.;Executive functions. Timepoint: in begging of study, 2nd, 7th, 14th, 28th of study. Method of measurement: (WCST) Wisconsin Card Sorting Test.;Selective attention and cognitive flexibility. Timepoint: in begging of study, 2nd, 7th, 14th, 28th of study. Method of measurement: Stroop test.;Memory. Timepoint: in begging of study, 2nd, 7th, 14th, 28th of study. Method of measurement: Digit Span. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Najmeh Shahini
Mashhad University of Medical sciences
Outcome results
None listed